HF
BDTX icon

HRT Financial’s Black Diamond Therapeutics BDTX Stock Holding History

HRT Financial’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,022
Closed -$25K – 4202
2026
Q1 		$25K Sell
12,022
-14,329
-54% -$34.1K ﹤0.01% 3545
2025
Q4 		$64K Buy
+26,351
New +$93.3K ﹤0.01% 2844
2024
Q2 		– Sell
-125,094
Closed -$634K – 2223
2024
Q1 		$634K Buy
+125,094
New +$504K ﹤0.01% 1134
2022
Q3 		– Sell
-10,298
Closed -$25K – 2806
2022
Q2 		$25K Buy
+10,298
New +$23.9K ﹤0.01% 2578
2021
Q4 		– Sell
-71,496
Closed -$604K – 3193
2021
Q3 		$604K Buy
71,496
+18,487
+35% +$183K ﹤0.01% 1813
2021
Q2 		$646K Buy
+53,009
New +$1.05M 0.01% 1542

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

HRT Financial's BDTX Position: Q2 2026 in Review

HRT Financial sold out of Black Diamond Therapeutics (BDTX) in Q2 2026, closing a stake of 12,022 shares — an estimated $25K sold.

HRT Financial first reported a position in BDTX in Q2 2021 and held it in 6 quarters. The position peaked at $646K in Q2 2021. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • HRT Financial reported no remaining Black Diamond Therapeutics position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 12,022 Black Diamond Therapeutics shares in Q2 2026, an estimated $25K.
  • HRT Financial first reported a position in Black Diamond Therapeutics in Q2 2021 and held it in 6 quarters.
  • HRT Financial's Black Diamond Therapeutics position peaked at $646K in Q2 2021.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.